This inventor holds 6 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Bundesrepublik Deutschland, Bundersrepublik Deutschland, Letzvertreten Durch Den Präsidenten Des Paul-Ehrlich-Instituts, Bundesrepublik Deutschland, Letztvertreten Durch Den Prasidenten Des Paul-Ehrlich-Instituts. Active years: 2003-2019.
Company Filing History:
3 out of 5 
1 out of 1 
1 out of 1 Years Active: 2003-2019
Title: Klaus Cichutek: Innovator in Gene Transfer Technologies
Introduction
Klaus Cichutek is a prominent inventor based in Langen, Germany. He has made significant contributions to the field of gene transfer technologies, holding a total of six patents. His work focuses on the pseudotyping of retroviral vectors, which has important implications for targeted gene therapy.
Latest Patents
Cichutek's latest patents include innovative methods for the pseudotyping of retroviral vectors with heterologous envelope proteins derived from the Paramyxoviridae family. This invention is based on the surprising discovery that incorporating F and H proteins with truncated cytoplasmic tails into lentiviral vector particles enhances the transduction efficiency of cells. Furthermore, these pseudotyped vector particles enable targeted gene transfer by modifying the H protein with a single-chain antibody or ligand that targets specific cell surface markers.
Career Highlights
Throughout his career, Klaus Cichutek has worked with notable organizations, including the Federal Republic of Germany and the Paul-Ehrlich-Institut. His expertise in the field has led to advancements in gene transfer methodologies that are crucial for therapeutic applications.
Collaborations
Cichutek has collaborated with esteemed colleagues such as Christian Buchholz and Roberto Cattaneo, contributing to the development of innovative solutions in gene therapy.
Conclusion
Klaus Cichutek's work in the field of gene transfer technologies exemplifies the impact of innovative thinking in medicine. His patents and collaborations continue to pave the way for advancements in targeted gene therapy.